The use of efavirenz as a part of late rescue antiretroviral treatment

HIV Clinical Trials

Volumn 2, Issue 5, 2001, Pages 413-420

  Manfredi, R ^a   Rizzo, E ^a   Calza, L ^a   Chiodo, F ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Efavirenz; HIV infection; Rescue treatment

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEW DRUG; NUCLEOSIDE ANALOG; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; VIRUS DNA; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DRUG DOSAGE FORM; DRUG EFFICACY; FEMALE; FOLLOW UP; GEL; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LONG TERM CARE; LYMPHOCYTE COUNT; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; T LYMPHOCYTE SUBPOPULATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VIREMIA; VIRUS INHIBITION;

EID: 0034795384     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/9VGB-WVPR-DNHQ-GVH7     Document Type: Article

References (36)

1. The year in review: Antiretroviral treatment
2. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA panel
3. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
4. Strategies for long-term success in the treatment of HIV infection
5. Substitution of protease inhibitors during treatment of patients with human immunodeficiency virus infection: Frequency, mode, reasons, and mid-term outcome
6. Antiretroviral drug resistance testing in adults with HIV infection
7. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure
8. Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use
9. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: Theory and practice
10. Impact of drug resistance mutations on virologic response to salvage therapy
11. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
12. CD4 cell counts at the third month of HAART may predict clinical failure
13. Salvage treatment against human immunodeficiency virus
14. Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients
15. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
16. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
17. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
18. Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors
19. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
20. Efavirenz and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response
21. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
22. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients
23. Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART
24. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug outcome
25. Salvage therapy in HIV-positive patients with a previous therapeutic experience with protease inhibitors
26. Four-drug salvage antiretroviral treatment including nelfinavir and efavirenz in highly treated children with congenital HIV disease
27. Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients
28. Clinical uses of non-nucleoside reverse transcriptase inhibitors
29. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
30. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development
31. Are nelfinavir-containing regimens effective as second-line triple therapy?
32. Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use
33. First-line nevirapine in combination with nucleoside analogues compared with nevirapine added to a salvage HAART
34. Changes in CD4+ and CD8+ T cells subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience
35. Clinical and immunological response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy
36. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection